EUDA Health (EUDA) vs Starling Oncology (STLN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Starling Oncology (STLN) has outperformed EUDA Health (EUDA) over the past year, losing 4.2% versus a loss of 71.8%. Starling Oncology is the larger company by market cap ($306.0 million vs $47.8 million), about 6.4 times the size, while EUDA Health is growing revenue faster (+70.0% vs +27.8%). Starling Oncology converts more of its revenue into profit, with a net margin of -12.1% versus -40.7%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | EUDA | STLN |
|---|---|---|
| Share price | $15.96 | $3.00 |
| Market cap | $47.79M | $305.97M |
| 1-day change | -7.69% | -5.66% |
| YTD return | -65.45% | -15.73% |
| 1-year return | -71.80% | -4.15% |
| 5-year return | — | -55.29% |
| Forward P/E | 9.97 | — |
| EPS (TTM) | $-1.18 | $-0.28 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $6.82M | $502.73M |
| Revenue growth (YoY) | +70.04% | +27.79% |
| Net income (latest FY) | $-2.77M | $-60.61M |
| Gross margin | 43.88% | — |
| Operating margin | -36.33% | -7.18% |
| Net margin | -40.65% | -12.06% |
| 52-week high | $68.00 | $7.13 |
| 52-week low | $5.26 | $2.32 |
| Distance from 52-week high | -76.53% | -57.92% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +244.61% | +208.33% |
| Average volume | 37.77K | 2.55M |
| Shares outstanding | 2.99M | 101.99M |
| Employees | 123 | 641 |
| Sector | Health Care | Health Care |
| Industry | Medical/Nursing Services | Medical/Nursing Services |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Starling Oncology is about 6.4 times larger than EUDA Health by market value ($305.97M vs $47.79M).
- STLN has outperformed EUDA by 67.6 percentage points over the past year.
- Starling Oncology is more profitable, keeping -12.1 cents of every revenue dollar as net income versus -40.7 cents for EUDA Health.
- EUDA Health grew revenue faster in its latest fiscal year (+70.04% vs +27.79%).
About EUDA Health
EUDA stock →EUDA Health Holdings Limited engages in the provision of non-invasive healthcare services primarily in Singapore, Malaysia, and China. It offers bioenergy cabin therapy packages; stem cell therapy services through third-party treatment centers; and holistic wellness consumer products and services.
Health Care · Medical/Nursing Services · 123 employees
About Starling Oncology
STLN stock →Starling Oncology, Inc., an oncology company, provides various oncology services in the United States. It operates through three segments: Specialty pharmacy, Patient Services, and Clinical Trials & Other.
Health Care · Medical/Nursing Services · 641 employees
EUDA vs STLN FAQ
Which is bigger, EUDA Health or Starling Oncology?
Starling Oncology (STLN) is larger, with a market capitalization of $305.97M compared with $47.79M for EUDA Health (EUDA).
Which stock has performed better over the past year, EUDA or STLN?
STLN returned -4.15% over the past 12 months, compared with -71.80% for EUDA (price return, excluding dividends). Past performance does not predict future results.
Are EUDA Health and Starling Oncology in the same industry?
Yes. Both are classified in the Medical/Nursing Services industry within the Health Care sector.